Tendulkar Prakash, Kant Ravi, Rana Satyavati, Yadav Poonam, Mirza Anissa A, Agarwal Disha
Internal Medicine, All India Institute of Medical Sciences, Rishikesh, IND.
Biochemistry, All India Institute of Medical Sciences, Rishikesh, IND.
Cureus. 2022 Jan 6;14(1):e20990. doi: 10.7759/cureus.20990. eCollection 2022 Jan.
Aim The aim of the study was to determine the efficacy of prokinetic agents in diabetic gastroparesis patients. Method This was a randomized open-label trial conducted on 50 patients with type 2 diabetes experiencing diabetic gastroparesis, which was diagnosed with the lactulose hydrogen breath test. After randomization, all 50 patients were divided into four arms (cinitapride, metoclopramide, levosulpiride, and domperidone) of different prokinetics and followed up for four weeks; after which, repeat gastroparesis cardinal symptom index score and orocecal transit time were recorded in order to assess the response to the treatment. Result There was no statistically significant difference among the four groups in terms of all the baseline characteristics except for gender (p=0.032). The follow-up gastroparesis cardinal symptom index was collected for 50 patients but repeat orocecal transit time could be performed only in 37 patients. In all four groups, there was a statistically significant (p<0.05) improvement in terms of orocecal transit time and gastroparesis cardinal symptom index scores. But there was no statistically significant difference in relative efficacy amongst these study groups. Conclusion Our study showed statistically significant improvement with four prokinetics drugs in terms of gastroparesis cardinal symptom index score and orocecal transit time, but there was no statistically significant benefit of one prokinetic drug over the other. Our study showed promising results with regard to prokinetic use in diabetic gastroparesis.
目的 本研究的目的是确定促动力药物对糖尿病胃轻瘫患者的疗效。方法 这是一项对50例2型糖尿病合并糖尿病胃轻瘫患者进行的随机开放标签试验,通过乳果糖氢呼气试验进行诊断。随机分组后,将所有50例患者分为四组(西尼必利、甲氧氯普胺、左舒必利和多潘立酮),分别使用不同的促动力药物,并随访四周;之后,记录重复的胃轻瘫主要症状指数评分和口盲肠传输时间,以评估治疗反应。结果 除性别外(p = 0.032),四组在所有基线特征方面均无统计学显著差异。收集了50例患者的随访胃轻瘫主要症状指数,但仅对37例患者进行了重复的口盲肠传输时间检测。在所有四组中,口盲肠传输时间和胃轻瘫主要症状指数评分均有统计学显著改善(p < 0.05)。但这些研究组之间的相对疗效无统计学显著差异。结论 我们的研究表明,四种促动力药物在胃轻瘫主要症状指数评分和口盲肠传输时间方面均有统计学显著改善,但一种促动力药物相对于另一种并无统计学显著优势。我们的研究显示了促动力药物在糖尿病胃轻瘫治疗中的良好前景。